Patents by Inventor Jerome Deval

Jerome Deval has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic pyridazinones and methods of use thereof
    Patent number: 11858913
    Abstract: Disclosed herein are compounds of Formula I: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: January 2, 2024
    Assignee: Aligos Therapeutics, Inc.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • Modulators of THR-? and methods of use thereof
    Patent number: 11840532
    Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a patient with one or more of the above compounds.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: December 12, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval
  • Oxindoles and methods of use thereof
    Patent number: 11793815
    Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: October 24, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • 2-pyridones and methods of use thereof
    Patent number: 11786532
    Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: October 17, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 11773126
    Abstract: Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: October 3, 2023
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: Leonid Beigelman, Jerome Deval, Marija Prhavc
  • Methods and compositions for targeting PD-L1
    Patent number: 11760764
    Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: September 19, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
  • Methods and compositions for targeting PD-L1
    Patent number: 11760761
    Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: September 19, 2023
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Jerome Deval, Cheng Liu, Qingling Zhang
  • METHODS AND COMPOSITIONS FOR TARGETING PD-L1
    Publication number: 20230065527
    Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Application
    Filed: August 12, 2021
    Publication date: March 2, 2023
    Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Jerome Deval, Cheng Liu, Qingling Zhang
  • METHODS AND COMPOSITIONS FOR TARGETING PD-L1
    Publication number: 20230031213
    Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Application
    Filed: June 15, 2022
    Publication date: February 2, 2023
    Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Cheng Liu, Jerome Deval, David McGowan
  • METHODS AND COMPOSITIONS FOR TARGETING PD-L1
    Publication number: 20230002413
    Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.
    Type: Application
    Filed: May 19, 2021
    Publication date: January 5, 2023
    Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
  • OXINDOLES AND METHODS OF USE THEREOF
    Publication number: 20220143031
    Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • BICYCLIC PYRIDAZINONES AND METHODS OF USE THEREOF
    Publication number: 20220144811
    Abstract: Disclosed herein are compounds of Formula I: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • 2-PYRIDONES AND METHODS OF USE THEREOF
    Publication number: 20220143032
    Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • COMPOUNDS TARGETING PRMT5
    Publication number: 20220112194
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 30, 2021
    Publication date: April 14, 2022
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing, Francois Gonzalvez
  • COMPOUNDS TARGETING PRMT5
    Publication number: 20220048922
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 28, 2021
    Publication date: February 17, 2022
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
  • MODULATORS OF THR-BETA AND METHODS OF USE THEREOF
    Publication number: 20220009924
    Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a patient with one or more of the above compounds.
    Type: Application
    Filed: July 8, 2021
    Publication date: January 13, 2022
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF
    Publication number: 20210395288
    Abstract: Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.
    Type: Application
    Filed: August 26, 2021
    Publication date: December 23, 2021
    Applicant: JANSSSEN BIOPHARMA, INC.
    Inventors: Leonid BEIGELMAN, Jerome DEVAL, Marija PRHAVC
  • Compounds targeting PRMT5
    Patent number: 11198699
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: December 14, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
  • MODULATORS OF THR-BETA AND METHODS OF USE THEREOF
    Publication number: 20210355112
    Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.
    Type: Application
    Filed: May 25, 2021
    Publication date: November 18, 2021
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 11149049
    Abstract: Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: October 19, 2021
    Assignee: JANSSEN BIOPHARMA, INC.
    Inventors: Leonid Beigelman, Jerome Deval, Marija Prhavc